Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of ($0.11), $0.13 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $37.9 million versus the consensus estimate of $38.95 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.